



The leading digital marketplace for prescription access and affordability, trusted by millions.

The Prescription Affordability Crisis

Prescription costs continue to rise, employers face unprecedented cost & coverage decisions, and over 900M prescriptions go unfilled each year in the U.S.¹

The GoodRx Solution

GoodRx makes prescriptions affordable and accessible, connecting consumers, pharmacies, pharma manufacturers, and plan sponsors.

How GoodRx Works

Aggregate low prices for all prescriptions

Pharma

250+
brand partners⁷

Pharmacies

~60k
pharmacy partners⁸

Connect with consumers & plan sponsors

Consumers

280M+
annual site visits⁹

Plan Sponsors

60%+
of commercially insured
lives reached via
integrated programs¹⁰

Key Consumer Products

Free Rx Savings

Subscriptions

How We Primarily Make Money

- Rx Transaction Fees (Consumer & Pharma Paid)
- Pharma Advertising
- Plan Sponsor Fees (Integrated Savings Programs)

- Consumer Subscription Fees

\$100B +

In savings
since inception²

#1

Prescription
app³

1.4M

Annual healthcare
professional users⁴

80% +

Consumer
awareness⁵

>70

Net promoter
score⁶

2026 Q2 Earnings Results

Q2 Revenue	Q2 Adjusted EBITDA ¹¹	Q2 Adjusted EBITDA Margin ¹¹	'26 Revenue Guidance	'26 Adjusted EBITDA Guidance ¹¹
\$200.4M	\$63.7M	31.8%	\$790-\$805M	\$240-\$250M
Pharma Direct +76% YoY Subscriptions +39% YoY			+\$22.5M from previous guidance midpoint	Previous guidance of >\$235M

**Deliver More
Consumer
Value via
Subscriptions**

**Scale
Pharma
Direct**

**STRATEGIC
FOCUS AREAS**

**Enhance
Plan Sponsor
Models**

**Stabilize
Prescription
Transaction
Revenue**

This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained on this page that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding our 2026 earnings guidance, our "Strategic Focus Areas" and related strategy and market opportunities. Important factors that may cause results to differ materially from those described in the forward looking statements are described under the heading "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2025 and our other SEC filings. 1. Number of annual adjusted unfilled prescriptions in 2025, based on internal analysis of the Utilization Management Report, 2018-2025, IQVIA Inc. All Rights Reserved. 2. As of Jan '26. Savings are measured as the difference between the pharmacy list price and the price the consumer pays utilizing a GoodRx code at the same pharmacy. 3. Based on the PYMNTS Provided Rankings of Prescriptions Apps, published in January 2024. 4. Based on internal data of the number of unique Healthcare Professionals site visits in 2025. 5. Based on an Aided Awareness internal study completed in 2025. 6. Net Promoter Score measured via an internal study, completed in 2024. 7. Brand partners as of January 2026. 8. Total number of pharmacies that accept GoodRx coupons, as of Jan '26. 9. Based on internal traffic data for 2025. Unique sessions across web, mobile web, and native app. 10. Commercial lives covered under contracted Integrated Savings Programs. 11. Adjusted EBITDA and Adjusted EBITDA Margin are non-GAAP financial measures and are presented for supplemental informational purposes only. Refer to "Non-GAAP Financial Measures" in our Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026 for definitions and reconciliations of Adjusted EBITDA and Adjusted EBITDA Margin to the most directly comparable GAAP measures. We have not reconciled our Adjusted EBITDA guidance to GAAP net income or loss because we do not provide guidance for such GAAP measure due to the uncertainty and potential variability of stock-based compensation expense, acquired intangible assets and related amortization and income taxes, which are reconciling items between Adjusted EBITDA and the most directly comparable GAAP measure. Because such items cannot be provided without unreasonable efforts, we are unable to provide a reconciliation of the non-GAAP financial measure guidance to the corresponding GAAP measure. However, such items could have a significant impact on our future GAAP net income or loss.

Strategic Focus Areas


KEY HIGHLIGHTS

SUBSCRIPTIONS

Delivering more consumer value through all-in-one solutions for prescriptions

Companion Subscription


Broad healthcare savings including Rx, Telehealth, Vision, and Dental



200 top generics RXs for free and majority of others for <\$10, in line with insurance pricing

Condition Subscription

All-in-one condition management




Condition Subscriptions offered for Weight Loss, Hair Loss, and Sexual Health

PHARMA DIRECT


Connecting Pharma manufacturers to the leading marketplace of prescription consumers

Consumer Direct Pricing
Savings **without** insurance coverage for brand medications



Transaction Fees

Integrated Savings
Savings **with** insurance coverage for brand medications



Advertising